What is Gen9bio?
Gen9bio is a San Jose, California-based entity specializing in DNA primer design. The company's offerings include TK antibody, DHH antibody, and anti-ager pAb, positioning it within the biotechnology and life sciences sector. Its focus on foundational biological tools suggests a role in advancing research and development within the genomics and antibody development fields. The company's history of diverse funding types, from debt to Series C, points to a complex financial strategy aimed at sustained development and market penetration.
How much funding has Gen9bio raised?
Gen9bio has raised a total of $50.4M across 6 funding rounds:
Private Equity
$500K
Debt
$2M
Series B
$1.6M
Debt
$395K
Private Equity
$21M
Series C
$25M
Private Equity (2009): $500K, investors not publicly disclosed
Debt (2010): $2M, investors not publicly disclosed
Series B (2011): $1.6M supported by PBM Capital Group and Draper Fisher Jurvetson
Debt (2012): $395K featuring Draper Fisher Jurvetson and PBM Capital Group
Private Equity (2013): $21M backed by Agilent, PBM Capital Group, The Kraft Group, and Draper Fisher Jurvetson
Series C (2014): $25M, investors not publicly disclosed
Key Investors in Gen9bio
Draper Fisher Jurvetson
Draper Fisher Jurvetson is a prominent venture capital firm known for investing in early-stage and growth-stage technology companies across various sectors, aiming to support transformative entrepreneurs.
PBM Capital Group
PBM Capital Group is an investment firm that has historically focused on companies within the life sciences and healthcare sectors, providing capital for development and expansion.
Agilent
Agilent Technologies is a global leader in life sciences, diagnostics, and applied markets, providing advanced instruments, software, and services to laboratories worldwide.
What's next for Gen9bio?
The substantial enterprise-level funding Gen9bio has attracted, particularly the recent strategic investment, signals a strong market validation and an accelerated path for scaling operations. This capital infusion is likely to fuel further innovation in its DNA primer design and antibody offerings, potentially expanding its research and development capabilities or market reach. The company's strategic financial backing suggests a focus on solidifying its position in the competitive biotech landscape and pursuing ambitious growth objectives.
See full Gen9bio company page
